source
- Xenon shares plunge 23% after voluntary hold on psychiatry trials, despite filing NDA for epilepsy drugXenon Pharmaceuticals announced that its lead asset azetukalner (AZK) has been submitted to the FDA as a new drug application for focal onset seizures. At the same time, the company disclosed a vo…
- Electra Therapeutics raises $350M in biotech IPO, fueling rare disease drug developmentElectra Therapeutics completed a $350 million initial public offering, becoming the 21st biotechnology company to go public in 2026. The strong demand for its shares highlights continued investor a…